Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

Discover the unexpected health benefits of diabetes and weight loss medications like Ozempic and Wegovy. Find out how these ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Epidermal growth factor receptor (EGFR) is a major driver of cancer dissemination and target for anti-cancer therapies but ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

The study's author suggested that, unlike subcutaneous fat or fat stored under the skin, fat stored in the muscles may be ...

Village Health Clubs & Spas dietitian Jamie Miller shares the top foods that naturally provide your body with GLP-1 without ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th ...